Leaflet NOVOSEVEN 2.4mg (120KUI) powder+solution for injection
Indicated for: bleeding; coagulation disorders
Route of administration: injectable
Substance: eptacog alpha activated (anticoagulant)
ATC: B02BD08 (Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
Eptacog alfa activated is a medication used to control and prevent bleeding in patients with hemophilia A or B with inhibitors, as well as in other rare coagulation disorders. It works by stimulating the formation of blood clots, helping to quickly stop bleeding.
It is administered intravenously under strict medical supervision, with the dose adjusted according to the severity of the bleeding and the patient's response.
Side effects may include injection site reactions, fever, headaches, increased risk of thrombosis, or, rarely, severe allergic reactions. Careful monitoring is necessary throughout the treatment.
Eptacog alfa activated is an essential option for patients with coagulation disorders, offering the chance to effectively control bleeding episodes and prevent serious complications.
General data about NOVOSEVEN 2.4mg (120KUI)
- Substance: eptacog alpha activated
- Date of last drug list: 01-07-2013
- Commercial code: W52382001
- Concentration: 120KUI
- Pharmaceutical form: powder+solution for injection
- Quantity: 1
- Product type: original
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for eptacog alpha activated
Concentrations available for eptacog alpha activated
- 100KUI
- 120KUI
- 240 KUI
- 250KUI
- 50KUI
- 60KUI